BAM15 vs Tesofensine
A side-by-side research comparison of BAM15 and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | Tesofensine |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 402.28 Da | 329.4 Da |
| Half-life | Short (hours in animal models) | 8-10 days |
| Bioavailability | Oral (animal studies) | High (oral ~93%) |
| Typical dose | Not established for humans | 0.25-0.5 mg |
| Frequency | Research protocols only | Once daily |
| Route | Oral (research) | Oral |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.